8-K: Ocuphire Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

Ocuphire Pharma announced its second quarter 2024 financial results and provided updates on its clinical programs, including the start of patient recruitment for the VEGA-3 Phase 3 trial.

Summary

• Ocuphire Pharma reported a net loss of $7.8 million for the second quarter of 2024, compared to a net loss of $5.0 million for the same period in 2023.
• The company's cash position was $41.4 million as of June 30, 2024, which is expected to fund operations into mid-2025.
• License and collaboration revenue was $1.1 million for the second quarter of 2024, down from $3.7 million in the same period of 2023.
• The decrease in revenue was primarily due to reduced reimbursement for research and development services from their commercial partner.
• General and administrative expenses decreased to $3.4 million from $4.3 million year-over-year, mainly due to reduced payroll and operating costs.
• Research and development expenses increased to $6.1 million from $4.7 million year-over-year, driven by increased manufacturing and toxicology costs for APX3330.
• The VEGA-3 Phase 3 trial for phentolamine ophthalmic solution in presbyopia has begun recruiting patients, with topline data expected in 2025.
• The LYNX-2 Phase 3 trial for phentolamine ophthalmic solution in dim light disturbances continues enrollment, also with topline data expected in 2025.
• Preparations are ongoing for a Phase 2/3 study of APX3330 in diabetic retinopathy, with discussions with the FDA regarding the Special Protocol Assessment (SPA).

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to increased losses and decreased revenue, although the company is making progress on its clinical programs and has a cash runway into mid-2025. The increased R&D spend is expected but the decrease in revenue is concerning.

Positives

• The company has a solid cash position of $41.4 million, providing a runway into mid-2025.
• The VEGA-3 Phase 3 trial has started recruiting patients, indicating progress in the presbyopia program.
• The LYNX-2 Phase 3 trial is experiencing strong enrollment, suggesting positive interest in the dim light disturbances treatment.
• The company is actively preparing for the next clinical study of APX3330 in diabetic retinopathy.
• Discussions with the FDA are ongoing regarding the SPA for APX3330, indicating a collaborative approach to regulatory approval.
• The company received a small royalty payment from sales of RYZUMVI, demonstrating some commercial traction.

Negatives

• The company experienced a net loss of $7.8 million for the second quarter of 2024, an increase from the $5.0 million loss in the same period of 2023.
• License and collaboration revenue decreased significantly to $1.1 million from $3.7 million year-over-year.
• Research and development expenses increased to $6.1 million, primarily due to increased costs for APX3330.
• The company's net loss per share increased to $(0.30) from $(0.24) year-over-year.

Risks

• The company's financial performance is subject to risks and uncertainties, including the success and timing of clinical trials and regulatory submissions.
• There is a risk that the company may not be able to obtain sufficient additional capital to continue to advance its product candidates.
• The company faces substantial competition and rapid technological change in the biopharmaceutical industry.
• The company's reliance on third parties for manufacturing and other services poses a risk to its operations.
• There are risks associated with the commercialization of any of Ocuphire's product candidates.
• The company's stock price may fluctuate significantly.

Future Outlook

The company anticipates that its current cash position will be sufficient to fund operations into mid-2025. Topline data from the VEGA-3 and LYNX-2 Phase 3 trials are expected in 2025.

Management Comments

• APX3330 has potential to be the first non-invasive, early treatment to delay vision-threatening complications in millions of patients with non-proliferative diabetic retinopathy.
• We are pleased with the progress on our preparations for the next clinical study.
• We continue to work collaboratively with the U.S. Food and Drug Administration (the FDA) on our submitted Special Protocol Assessment (SPA) for Phase 2/3 and the overall clinical development plan for APX3330.
• We are also making progress on additional indications for phentolamine ophthalmic solution.
• Phentolamine ophthalmic solution has demonstrated a differentiated product profile in prior presbyopia studies, and we believe it could be a promising and convenient treatment option for the growing number of people with this condition.
• The LYNX-2 Phase 3 study in dim light disturbances (DLD) has seen strong enrollment and could provide a differentiated product for patients.

Industry Context

Ocuphire is operating in the competitive ophthalmic biopharmaceutical space, focusing on developing treatments for retinal and refractive eye disorders. The company's focus on non-invasive treatments for diabetic retinopathy and novel solutions for presbyopia and dim light disturbances aligns with current trends in the industry. The company is competing with other companies developing treatments for similar conditions.

Comparison to Industry Standards

• Ocuphire's cash runway into mid-2025 is typical for a clinical-stage biotech company, but the burn rate is increasing.
• The increase in R&D expenses is consistent with companies advancing clinical programs, but the decrease in revenue is concerning.
• The company's focus on phentolamine ophthalmic solution for presbyopia and dim light disturbances is similar to other companies exploring novel treatments in these areas, such as those developing eye drops for presbyopia.
• The company's APX3330 program for diabetic retinopathy is competing with other companies developing treatments for this condition, including both small molecule and biologic approaches.
• The company's clinical trial timelines are consistent with industry standards for Phase 3 trials, with topline data expected in 2025.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue.
• Employees may be impacted by the company's financial performance and future prospects.
• Customers and patients may benefit from the company's clinical programs if successful.
• Suppliers and creditors may be impacted by the company's financial health.

Next Steps

• Continue patient recruitment for the VEGA-3 Phase 3 trial.
• Continue enrollment in the LYNX-2 Phase 3 trial.
• Advance preparations for the Phase 2/3 study of APX3330 in diabetic retinopathy.
• Continue discussions with the FDA regarding the SPA for APX3330.
• File the Quarterly Report on Form 10-Q with the Securities and Exchange Commission.

Key Dates

Keywords

Ocuphire Pharma, ophthalmic, biopharmaceutical, APX3330, phentolamine ophthalmic solution, diabetic retinopathy, presbyopia, dim light disturbances, clinical trials, VEGA-3, LYNX-2, RYZUMVI, FDA, financial results